Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIX 
Anixa Biosciences Inc (ANIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ANIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.71% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 95.67M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 3 | Beta 0.44 | 52 Weeks Range 2.07 - 4.20 | Updated Date 08/15/2025 |
52 Weeks Range 2.07 - 4.20 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.75% | Return on Equity (TTM) -65.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82867830 | Price to Sales(TTM) 481.54 |
Enterprise Value 82867830 | Price to Sales(TTM) 481.54 | ||
Enterprise Value to Revenue 368.98 | Enterprise Value to EBITDA -8.76 | Shares Outstanding 32211100 | Shares Floating 30462674 |
Shares Outstanding 32211100 | Shares Floating 30462674 | ||
Percent Insiders 5.43 | Percent Institutions 17.4 |
Upturn AI SWOT
Anixa Biosciences Inc
Company Overview
History and Background
Anixa Biosciences, Inc. (ANIX) is a biotechnology company focused on developing therapies and diagnostics that address critical unmet needs in oncology and infectious diseases. The company was formerly known as ITUS Corporation and changed its name in January 2017. It focuses on innovative approaches to cancer therapy and prevention.
Core Business Areas
- Cancer Immunotherapy: Developing therapies designed to use the body's immune system to fight cancer. This includes programs targeting ovarian cancer and other solid tumors using chimeric antigen receptor T-cell (CAR-T) technology and an ovarian cancer vaccine licensed from Cleveland Clinic.
- Infectious Diseases: Focuses on developing a novel therapy for treating infectious diseases and diagnostics to better monitor a body's immune response to treat infectious diseases.
- Cancer Diagnostics: Developing diagnostic tools for early cancer detection.
Leadership and Structure
The leadership team includes individuals with experience in biotechnology, pharmaceuticals, and finance. The company structure typically consists of a CEO, CFO, CSO, and other key management roles overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- CAR-T Therapy for Ovarian Cancer: Anixa is developing a CAR-T therapy targeting Follicle Stimulating Hormone Receptor (FSHR), which is expressed in ovarian cancer cells. Currently this product is in preclinical phases. Competitors include companies pursuing CAR-T therapies for solid tumors, such as Kite Pharma (GILD), Novartis (NVS), and Bristol Myers Squibb (BMY), but no product has yet received FDA approval.
- Ovarian Cancer Vaccine: Anixa licensed an ovarian cancer vaccine technology from Cleveland Clinic that targets the C7 epitope of the mucin 16 protein (MUC16), which is expressed in ovarian cancer cells. This product is in preclinical development. Competition comes from companies with different approaches to cancer vaccines.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high innovation and regulation, with a focus on drug and diagnostic development for various diseases. It is subject to extensive clinical trials, regulatory approvals, and market adoption challenges. The oncology market is large and growing, driven by aging populations and advances in cancer treatment.
Positioning
Anixa Biosciences is positioned as an innovative biotechnology company focusing on unmet needs in oncology and infectious diseases. Its strategy is to license promising technologies and advance them through preclinical and clinical development. Competitive advantages may include its novel approach to CAR-T therapy and ovarian cancer vaccine. However, being smaller than large pharmaceutical companies puts it at a disadvantage in resourcing projects.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. The ovarian cancer therapeutics market alone is projected to grow significantly. Anixa's TAM will depend on the success and market penetration of its products and the size of the markets for these specific treatments and diagnostic tools.
Upturn SWOT Analysis
Strengths
- Innovative therapeutic approaches (CAR-T and vaccine)
- Partnerships with leading research institutions
- Focus on unmet medical needs in cancer
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early-stage development pipeline, high risk of failure
- Reliance on licensing agreements for key technologies
- Limited commercialization experience
Opportunities
- Potential to disrupt established cancer treatment paradigms
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion of pipeline through additional licensing or acquisitions
- Growing demand for personalized cancer therapies
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Intellectual property challenges
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
- MRNA
Competitive Landscape
Anixa is a smaller player in a competitive landscape dominated by large pharmaceutical companies. Its competitive advantage lies in its innovative technologies and focus on unmet needs. It faces challenges in competing with larger companies for resources and market share.
Growth Trajectory and Initiatives
Historical Growth: Anixa's historical growth is characterized by increasing research and development activity and expansion of its pipeline. Financial growth is dependent on securing funding.
Future Projections: Future growth will depend on the success of its clinical trials and regulatory approvals, as well as its ability to commercialize or partner its technologies. Analyst estimates will focus on sales forecasts for successful products.
Recent Initiatives: Recent initiatives will include advancing CAR-T and vaccine programs through clinical trials, securing partnerships, and exploring new therapeutic areas.
Summary
Anixa Biosciences is a development-stage biotechnology company focused on cancer immunotherapy and infectious diseases. The company's CAR-T and vaccine technologies hold promise, but are in early stages and carry significant risk. Its financial performance depends on raising capital and achieving clinical milestones. Investors should be aware of the inherent risks of investing in a company with a limited track record of commercial success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Analyst reports
- Industry databases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The information is based on publicly available data and is subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anixa Biosciences Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 1987-01-01 | CEO, Chairman & Co-Chair of CBAB Dr. Amit Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.anixa.com |
Full time employees 5 | Website https://www.anixa.com | ||
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.